**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 47612**

**Manuscript Type: REVIEW**

**Recent advances in gastric cancer early diagnosis**

Necula L *et al.* New biomarkers in gastric cancer

Laura Necula, Lilia Matei, Denisa Dragu, Ana I Neagu, Cristina Mambet, Saviana Nedeianu, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu

**Laura Necula, Lilia Matei, Denisa Dragu, Ana I Neagu, Cristina Mambet, Saviana Nedeianu, Coralia Bleotu, Carmen C Diaconu, Mihaela Chivu-Economescu,** Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, Bucharest 030304, Romania

**Laura Necula,** Faculty of Medicine, Titu Maiorescu University, Bucharest 040441, Romania

**ORCID number:** Laura Necula (0000-0001-6531-7939); Lilia Matei (0000-0003-4479-655X); Denisa L Dragu (0000-0002-5868-2636); Ana I Neagu (0000-0001-6126-8973); Cristina Mambet (0000-0001-8495-7704); Saviana Nedeianu (0000-0001-8751-524X); Coralia Bleotu (0000-0002-9031-338X); Carmen C Diaconu (0000-0002-2259-1425); Mihaela Chivu-Economescu (0000-0001-7512-4700).

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Supported by** a grant of the Romanian National Authority for Scientific Research and Innovation, CNCS - UEFISCDI, No. PN-III-P4-ID-PCCF2016-0158 (contract PCCF 17/2018), within PNCDI III.

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author:** **Mihaela Chivu-Economescu, PhD, Research Assistant Professor, Research Scientist, Senior Researcher,** Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, 285 Mihai Bravu Ave, Bucharest 030304, Romania. mihaela.chivu@gmail.com

**Telephone:** +40-21-3242590

**Fax:** +40-21-3242590

**Received:** March 19, 2019

**Peer-review started:** March 19, 2019

**First decision:** March 27, 2019

**Revised:** April 3, 2019

**Accepted:** April 19, 2019

**Article in press:**

**Published online:**

**Abstract**

Gastric cancer (GC) remains an important cause of cancer death worldwide with a high mortality rate due to the fact that the majority of GC cases are diagnosed at an advanced stage when the prognosis is poor and the treatment options are limited. Unfortunately, the existing circulating biomarkers for GC diagnosis and prognosis display low sensitivity and specificity and the GC diagnosis is based only on the invasive procedures such as upper digestive endoscopy. There is a huge need for less invasive or non-invasive tests but also highly specific biomarkers in case of GC. Body fluids such as peripheral blood, urine or saliva, stomach wash/gastric juice could be a source of specific biomarkers, providing important data for screening and diagnosis in GC. This review summarized the recently discovered circulating molecules such as microRNAs, long non-coding RNAs, circular RNAs, which hold the promise to develop new strategies for early diagnosis of GC.

**Key words:** Biomarkers; Gastric cancer; Early diagnosis; Genetic and epigenetic alterations; Circulating molecules

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Despite the fact that in the last decades, gastric cancer (GC) has shown a decreasing incidence, the five-year survival rate continues to remain poor mainly because most patients are asymptomatic until the disease progresses to advanced stages. Recent progress in molecular landscape of GC and improved detection methods may facilitate screening and diagnosis of GC in early stages. Numerous studies aim to identify specific non-invasive biomarkers from alternative sources such as peripheral blood, urine or saliva, stomach wash/gastric juice. This review summarized the recently discovered circulating molecules which hold the promise to develop new strategies for early diagnosis of GC.

Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, Bleotu C, Diaconu CC, Chivu-Economescu M. Recent advances in gastric cancer early diagnosis. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Gastric cancer (GC) remains a challenge for oncology domain being the fifth most frequently diagnosed cancer (1033701 new cases in 2018) and the third leading cause of cancer death (782685 deaths) of all malignancies worldwide[1]. Although over the last decades GC has shown a decreasing incidence, the five-year survival rate continues to be poor, being estimated at 10% for patients with advanced GC. In the developed countries, like Japan, where early diagnosis of GC reaches 50%, the five-year survival rate attains 90%[2].

 Currently, the most frequent tumor markers used in the clinic for early detection of GC comprise carcinoembryonic antigen (CEA), the carbohydrate antigens (CA) - CA19-9, CA72-4, CA125, CA24-2, CA50, and also pepsinogen and α-fetoprotein (AFP)[3]. However, the specificity and sensitivity of these serum biomarkers are poor and so far, none of them is unique for GC diagnosis[3,4]. Thereby, the development of improved detection method to diagnose CG in early stages is crucial, especially knowing that most patients are asymptomatic until the disease progresses to advanced stages. Moreover, GC is a complex, heterogeneous disease, involving multiple genetic and epigenetic alterations[5].

 Recently, the use of high throughput technologies has brought new insights into the molecular pathogenesis, resulting in a new molecular classification of gastric adenocarcinoma into four subtypes, based on their genomic features. According to The Cancer Genome Atlas (TCGA), GCs are divided in Epstein-Barr virus (EBV)-infected tumors, microsatellite instability tumors (MSI), genomically stable tumors (GS), and chromosomally unstable tumors (CIN)[6]. The Asian Cancer Research Group (ACRG) categories GC into MSI tumors and Microsatellite Stable (MSS) tumors with either epithelial-to-mesenchymal transition (MSS/EMT), TP53 activity (MSS/TP53+), or TP53 inactivity (MSS/TP53-)[7,8]. This new classification opened the way for several clinical trials that are trying to define new therapeutic regimens combining immune checkpoint inhibitors with molecular targeted therapies, with promising results[9]. However, early diagnosis remains mandatory, and studies aiming to identify new biomarkers or genetic signatures are imperative.

 Genetic alterations, including large chromosomal gain or loss, single nucleotide variations, and mutations, as well as epigenetic alterations, like aberrant DNA methylation, histone modification, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) overexpression or down-regulation, were described as major aspects implicated in GC initiation and progression[10].

 A better understanding of the molecular factors involved in gastric carcinogenesis can lead to the identification of novel biomarkers for early GC diagnosis or markers use for prognosis and for monitoring therapy response. This review aims to discuss the most important types of molecules secreted from the tumor tissues to the body fluids, which candidates as circulating biomarkers for early diagnosis of GC (Figure 1).

**CIRCULATING PROTEOMIC BIOMARKERS IN EARLY GC**

Although several circulating tumor-associated antigens have entered routine clinical practice for a long time their utility in early detection of GC remains elusive, due to the high incidence of false-positive and false-negative results[11,12]. CEA, CA19-9, and CA72-4 are the most frequently used conventional tumor markers in GC diagnosis, prognosis, therapeutic monitoring and detection of recurrences[13]. At diagnosis, both CEA and CA 19-9 levels can provide useful prognostic information regarding the depth of tumor invasion and the presence of metastases[14,15]. However, they do not represent effective tools for GC screening and early diagnosis as they do not display enough sensitivity and specificity under these circumstances[16,17]. CA72-4 was shown to exhibit higher sensitivity and accuracy than CEA, yet there are only few studies that investigated its relevance in GC screening[18]. Other tumor markers, such as AFP and CA125 proved to have very low positivity rates in early GC[19]. Also, CA50 is of limited diagnostic value[20].

 To increase the diagnostic performance for GC different combinations of serological tumor markers were employed. In this respect, it was shown that by combining CEA, CA19-9, and CA72-4 with thymidine kinase 1 (TK1) - a biomarker of cell proliferation - a significant increase in sensitivity and specificity of GC detection was obtained, compared to the isolated use of the biomarkers[21]. Recently, a diagnostic model including the serum levels of CEA, CA72-4 and of three inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-8] was proposed for early GC detection. In the validation study, this model provided good discrimination between healthy controls, atypical hyperplasia of gastric mucosa, early-stage GC and advanced-stage GC groups[22].

 Concerning the use of stomach-specific biomarkers, measurement of serum pepsinogens (PGs) is the most common non-invasive method employed for GC detection, although it identifies individuals with gastric precancerous lesions, rather than GC itself[23]. Thus, low levels of pepsinogen I (PGI) and a low pepsinogen-I to pepsinogen ratio (PGI/PGII) exhibit a good correlation with atrophic changes in the gastric corpus, while their accuracy for GC detection is low[24]. Additionally, gastrin-17 (G-17) was proposed as an indicator antral atrophy[25]. As shown recently, a biomarker panel comprising PGI, PGII, PGI/PGII, G-17 and IgG antibodies to *Helicobacter pylori* (*H. pylori*) represents a promising non-invasive tool to stratify individuals at high risk for GC development[26]. Also, serum levels of trefoil factor 3 (TFF3), a protein ectopically expressed in intestinal metaplasia of the stomach[27], was found to display better performance in GC detection than PGs[25], and the combination of TFF3 with PGs demonstrated even higher sensitivity for early GC[28].

 Other potential circulating biomarkers for detecting early-stage GC include M2-pyruvate kinase, a tumor-associated metabolic marker; the adipocytokine leptin as an independent biomarker of intestinal metaplasia; p-53 autoantibody; the cell-cycle-related protein RegIV; the inflammatory signaling molecules olfactomedin 4 and vascular adhesion protein-1 (VAP-1)[29].

 A different approach to identify early GC biomarkers has involved mass spectrometry for analyzing serological glycomic profiles in GC patients and non-cancer controls. Significant differences in serum N-glycans were observed between the two groups. Moreover, the decreased core fucose was validated as a potential biomarker for distinguishing early-stage GC patients from healthy controls[30].

**ONCOGENES/TUMOR SUPPRESSORS IN GC**

The development of state-of-the-art techniques holds the promise of new molecular markers identification that are able to diagnose early, predict the disease outcome and help access the appropriate therapy. Numerous studies showed an increased level of expression of oncogenes in GC. They stimulate tumor cell growth and cell cycle and inhibit apoptosis.

 Recent studies identified several genes whose elevated expression level proved to be associated with GC and might be useful in early detection, such as *xpg*, interferon-induced transmembrane protein 1 (*iftim1*), matrix metalloproteinase-9 (*mmp-9*), pituitary tumor-transforming gene-1 (*pttg1*), *stc1*[31].

 XPG/ERCC5 (13q33) Xeroderma pigmentosum group G/excision repair cross-complementing group 5, an enzyme from NER (nucleotide excision repair) system, is involved in repairing of DNA lesions caused by genomic instability. The gene expression level of *ercc5* was found to be significantly higher in GC compared to gastritis, and it was associated with tumor development and progression[32].

 By microarray profiling methods, *ifitm1* was identified as a gene upregulated in tumor cell lines and GC tissues. Moreover, important differences in expression level in intestinal vs diffuse type of GC were observed. Although the role of this gene in tumorigenesis is not clearly understood, *ifitm1* raised expression was implicated in invasion and migration of GC cells[33] and was also related to increased inflammatory responses that may play a part in tumor progression.

 MMP-9 is an enzyme that contributes to the degradation of the extracellular matrix, having a well-known role in tumor growth, invasion and metastasis in gastric carcinoma[34]. A study that evaluates both serum and tissue expression level of MMP-9, found out a correlation between serum concentration of MMP-9 before surgery and TNM staging. Although the *mmp-9* expression level in gastric tumor was higher compared to healthy tissue, and positively associated with depth of invasion, it did not correlate significantly with MMP-9 serum level[35].

 A recently discovered proto-oncogene, *pttg1* can affect tumorigenesis, invasion, and metastasis of many cancer types. The expression of *pttg1* is upregulated in gastric tumor tissue compared to gastric intraepithelial neoplasia and normal mucosa (both mRNA and protein level) and it is an independent factor for survival. PTTG1 might represent a potential diagnostic marker and a therapeutic target[36].

 STC1 and STC2, members of STC (stanniocalcin) family, were highly expressed in numerous cancer types. In GC, both STC1 and STC2 expression is upregulated, STC1 being significantly associated with tumor staging, metastasis, and progression-free survival. Serum level of STC1 was significantly elevated in preoperative cancer patients compared to benign gastric cases and decreased 7-10 d after surgery[37]. Arigami *et al*[38] reported a significantly higher number of *stc1* mRNA copies in the blood of GC patients *vs*. normal controls that correlates with tumor invasion and staging and has a greater sensitivity than CA 19-9 and CEA. These studies suggest the utility of serum STC1 as diagnosis and prognosis marker in GC.

 Using gene microarray, our group also identified a panel of overexpressed genes associated with tumor progression: KRT17, COL10A1, KIAA1199, SPP1, IL11, S100A2, and MMP3. From these, COL10A1, KRT17, and SALL4 candidate as biomarkers for early detection having an increased expression in the early stages of gastric tumorigenesis[39]. COL10A1 was found elevated in serum of patients with colorectal cancer[40], proven to be a worthy circulating biomarker for early diagnosis. KRT17 was also demonstrated to be involved in tumor growth, motility, and invasion by *in vitro* and *in vivo* studies on gastric tumorigenesis[41].

 Tumor suppressor genes can present loss of expression in GC patient samples that result in accelerated cell growth, the progression of the cell cycle, and decreased inhibition of the oncogene expression. These alterations were also studied in order to discover new diagnostic molecular markers for the early detection and progression of GC[31].

 Using a gene microarray analysis, one study identified transmembrane protein with EGF like and two follistatin-like domains 2 (*tmeff2*) as a gene with significantly decreased expression in GC tissues, negatively correlated with the advanced cancer stage, large tumor size, and poor prognosis. The authors showed that the increase of *tmeff2* expression decrease cell proliferation by increasing apoptosis and by blocking the cell cycle in GC cells[42]. Moreover, modification of *tmeff2* expression in GC seems to be associated with *H. pylori* infection *via* STAT3 activation[43].

 An interesting possible biomarker is gastrokine 1 (GKN1), a small protein significantly expressed in the surface lumen epithelial cell layer of gastric tissue, being involved in the maintenance of mucosal integrity and secreted into the stomach, but absent in GC[44]. It was also detected that GKN1 acts as a tumor suppressor and a modulator of apoptotic signals in GC, its lower expression might be considered an indicator of increased risk of gastric carcinogenesis[45].

 Another study suggested the opportunity of detecting GC using the gene expression profile of the blood. In this study, a four-gene panel discriminated GC with an accuracy of 95%, sensitivity of 92% and specificity of 96%. This four-gene panel for detection of GC includes two overexpressed genes: purine-rich element binding protein B(*purb*) and structural maintenance of chromosomes 1A (*smc1l1*), and two underexpressed genes: DENN/MADD domain containing 1B(*dennd1b*) and programmed cell death 4 (*pdcd4*)[46].

 Next-generation deep sequencing was used to evaluate mutations of *tp53* in tumor biopsies, plasma and stomach fluids (gastric wash) obtained from GC patients. The results showed that *tp53* mutations were identified in 15/46 biopsies (32.6%), 7/46 gastric wash - (15.2%) and 6/46 plasma samples (13%). The authors suggested that gastric wash could be useful to detect DNA alterations using a comprehensive gene-panel designed for GC diagnosis[47].

**METHYLATION PATTERN OF GC**

In GC, epigenetic alteration by methylation occurs in specific genes involved in various processes such as cell cycle regulation (*p16nk4a, tcf4*), DNA repair (*hmlh1* and *mgmt*), cell growth/differentiation (*hoxd10, hai-2/spint2, ndrg2*), transcriptional regulation (*hltf, pax6, znf545, runx3*), cell adhesion/invasion/migration (*cdh1, cdh4, apc, flnc, lox, timp3, tsp1*), apoptosis (*bnip3, xiap, bnip3, bcl2, cacna2d3, dapk, gpx3, pcdh10, pcdh17, casp8, xaf1*), angiogenesis (*thbs-1* and *p73*), STAT pathway (*socs-1*), Ras pathway (*rassf1a, rassf2, hdab2ip, rkip*), Wnt pathway (*dkk-3, ctnnb1*), as well as in multidrug resistance genes (*mdr1, gstp1*)[48,49] and in genes associated with Epstein-Barr virus-type tumors (*pycard, bmpr1a,* and *pgr*) or *H. pylori*positive tumors(*brinp1, epha5, fli1,* and *sez6l*)[50]. The correlation of these biomarkers with tumor size, localization, differentiation, invasion, lymph node metastasis, distant metastasis, TNM stage, and prognosis is presented in Figure 2.

 It was demonstrated previously that, in the case of gastric tumors, aberrant DNA methylation occurs more frequently than mutations[51], making DNA methylation a more specific assay in detection of such disease. Therefore, researchers started looking for an easier and less invasive method for the collection of cells and detection of DNA originated from gastric tumors. In serum/plasma DNA obtained from GC patient was observed a significantly higher methylation level of some biomarkers, such as *p16, cdh1, mgmt, rarb,* and *rnf180*[52].

 Previously it was considered that DNA is denatured by stomach acidity[53], later on, it was demonstrated that this process is true in case of normal cells, but incorrect in case of DNA from tumor cells[45]. Collection of samples from stomach wash during endoscopy demonstrated that cancer cells from mucosal layers are easier exfoliated than normal cells into gastric juice and also that DNA isolated from such tumor cells is less degraded due to acidity[45] making it easy to be studied, offering a sensitive and quantitative method of detection.

 Several genes were found to be methylated with higher frequency in gastric neoplasia versus normal condition and therefore were analyzed as possible biomarkers. Among them six methylated genes were most specific and sensitive for GC: *adam23, mint25, gdnf, prdm5, mlf1* and *rora*. The results have shown that the combination of the markers *mint25 + adam23 + gdnf* achieved a high sensitivity (95%) and speciﬁcity (92%). It was found that the methylation process is gene- and tumor stage-dependent during gastric carcinogenesis, some genes are highly methylated during dysplasia and early cancer phase compared with normal, but show lower methylation in advanced GC, similar with mechanism observed in ulcerative colitis-associated colon neoplasia[45].

 But increased methylation process could have other causes as well, such as chronic inflammation of gastric mucosae, especially by *H. pylori* infection and aging. In order to test the effect of inflammation on methylation, the BarH-like 2 homeobox protein (*barhl2*) gene was chosen since is an *H. pylori*-independent biomarker. The *barhl2* methylation analysis of exosomal DNA (exoDNA) derived from gastric juice proven that the process is not influenced by atrophy of the gastric mucosa or *H. pylori* infection and could be used as a biomarker for detection of both early and advanced GC[54].

**MIRNAS AS DIAGNOSTIC BIOMARKERS FOR GC**

MiRNAs represent a class of small non-coding RNAs (19-25 nucleotides) involved by epigenetic mechanisms in many cellular processes, such as differentiation, proliferation, and apoptosis. These molecules, that seem to present specific expression signatures in normal and tumor gastric tissue, can act as oncogenes and/or tumor suppressors depending on the role of the target mRNA/gene[55].

 More studies suggested that miRNAs could be considered important potential biomarkers for gastric pathology as they are frequently found to be deregulated in gastric tissue in *H. pylori* infection, chronic gastritis, preneoplastic conditions such as atrophic gastritis and intestinal metaplasia, and also in early dysplasia and invasive cancer. Moreover, modifications of miRNA blood levels were also identified in GC patients supporting the development of new diagnostic and prognostic methods based on miRNA expression analysis[56].

 A promising result was obtained by a study in which miRNA-21 levels, in serum and peripheral blood mononuclear cells, were found to be increased in GC patients with a positive prediction rate around 90%, while those of CA199 and CEA were around 50%. Moreover, circulating miR-21 levels can discriminate between stage I and stage IV of GC[57].

 miR-376c was found to be up-regulated in tissue, plasma, and urine of GC patients, even from the early stage of the tumor. The increased expression of miR-376c was associated with the proliferation, migration and anchorage-independent growth of cancer cells, having as a direct target *arid4a* gene which is considerably down-regulated in tumor tissue[58].

 Increased pre-operative circulating miR-196a and miR-196b levels were identified in GC patients compared to healthy controls, the expression level of these miRNAs being reduced after the surgical resection of the gastric tumor. Interestingly, higher circulating miR-196a/b levels were correlated with the metastatic potential of the tumor, advanced stages, and poorer survival. Moreover, the results of this study suggested that circulating miR-196a, miR-196b, and combined miR-196a and miR-196b can distinguish between GC patients and healthy controls with higher sensitivity and specificity compared to the CEA or CA19-9[59]. Another recent study analyzed circulating miRNA levels in GC patients and identified a four-miRNA panel (miR-501-3p, miR-143-3p, miR-451a, miR-146a) as possible noninvasive biomarkers for prediction and prognosis of lymph node metastasis (LNM). In addition, LNM patients with decreased levels of miR-451a and miR-146a presented worse overall survival[60]. A five-miRNA panel (miR-16, miR-25, miR-92a, miR-451, and miR-486-5p) was found to be differentially expressed in plasma of gastric non-cardia adenocarcinoma patients compared to healthy controls. This panel seems to be able to discriminate between early-stage of gastric non-cardia adenocarcinoma patients and cancer-free subjects[61]. Other panels containing up-regulated miRNAs (miR-200a-3p, miR-296-5p, miR-132-3p, miR-485-3p, and miR-22-5p)[62] and (miR10b-5p, miR132-3p, miR185-5p, miR195-5p, miR-20a3p, and miR296-5p)[63] were identified in serum of the GC patients compared to healthy controls. Based on the evidence that exosomes secreted by cancer and normal cells can be released into the circulatory system, a recent study identified overexpression of circulating exosomal miR-19b and miR-106a in GC patients compared to healthy controls. These increased levels were correlated with lymphatic metastasis and advanced stages of GC[64].

 miR-146, miR-375, and Let-7 were found to be downregulated while miR-19 and miR-21 presented an increased expression in plasma of the GC patients with *H. pylori* infection. The study also identified overexpression of the genes involved in IRAK4 signaling and a decreased expression of *pten* gene in the GC patients with *H. pylori* infection compared to the control group, suggesting the potential of these molecules as biomarkers for early diagnosis of GC[65]. There are also other molecular potential biomarkers for screening GC identified in gastric juice: miR-421, miR-21, miR-106a and miR-129[66].

 Table 1 summarized several miRNAs presenting modified circulating expression in GC patients compared to healthy controls.

 Even if these results need to be validated by independent groups or cohorts in prospective studies, circulating miRNAs could be considered a class of novel, non-invasive diagnostic biomarkers with sufficient diagnostic accuracy in detecting the early-stage GC.

**LNCRNAS IN GC**

LncRNAs are transcripts longer than 200 nucleotides with no or limited protein-coding potential. lncRNAs are implicated in the regulation of several biological processes like transcription and translation, cellular differentiation, gene expression, cell cycle, *etc*[71]. They are characterized by high stability while circulating in body fluids and their level in tumor tissue correlates with plasma levels. As such, lncRNAs can be used to distinguish tumor patients at early stages from healthy people, as well as to predict the prognostic, metastasis risks and recurrence after surgery[72,73].

 In 2013, Cao *et al*[74] investigated the lncRNA expression in GC and detected 88 differentially expressed lncRNAs, 71 upregulated and 17 downregulated. Zhou *et al*[75] hypothesized that GC-related lncRNAs might be released into the circulation during tumor initiation and could be utilized to detect and monitor GC.

 Highly upregulated in liver cancer (HULC) is a lncRNA implicated in the growth and tumorigenesis of human GC. *In vitro* overexpression of HULC in gastric cell lines stimulates proliferation and invasion, inhibits cell apoptosis and can induce autophagy patterns, while its silencing reverses the EMT phenotype[76]. Evaluated in plasma, HULC level is higher in preoperative patients compared with healthy control subjects[77].

 Another candidate as a possible biomarker for early detection and prognosis prediction of GC is lncRNA PVT1 since the levels of PVT1 in gastric juice from gastric patients were signiﬁcantly higher than those from normal subjects[78].

 Zhou *et al*[75] proposed H19 (imprinted maternally expressed transcript) as a potential biomarker for diagnosis of GC, especially for early tumor screening. It stimulates cell proliferation and inhibits apoptosis[79]. H19 plasma level is significantly higher in GC patients compared with normal controls[75,80-82] and allows the discrimination of early stage GC[75]. On the other side, H19 plasma levels were significantly lower in postoperative samples than in preoperative ones[75,80]. Also, patients with smaller tumor sizes (< 5 cm) exhibit higher H19 level in their circulation compared with those with larger tumors (≥ 5 cm)[81].

 Another abnormally expressed lncRNA in GC is long intergenic non-protein-coding RNA 152 (LINC00152), its plasma level being significantly elevated in GC patients compared with healthy controls[83,84] and presenting higher levels in postoperative plasma samples compared with preoperative ones[83]. This lncRNA allows differentiating GC patients from ones with benign gastric diseases and can be also detected in gastric juice[84]. Another lncRNA that can be detected in gastric juice is AA174084 characterized by higher levels in GC patients compared with healthy or other non-GC subjects. Its plasma level drops markedly in GC patients on day 15 post-surgery and is associated with invasion and lymphatic metastasis[85].

 Hox transcript antisense intergenic RNA (HOTAIR) has been suggested to be implicated in GC tumorigenesis and progression[86]. It promotes cell pro­liferation and inhibits apoptosis[79]. HOTAIR plasma level is significantly higher in GC patients compared with healthy controls. Moreover, increased HOTAIR expression was associated with advanced tumor stages, higher grades, and metastasis[86]. Other up-regulated lncRNAs are human urothelial carcinoma associated 1 (UCA1), which is implicated in GC carcinogenesis and presents higher levels in GC patients[87], and ABHD11-AS, whose levels in gastric juice is significantly higher in GC patients, being also associated with clinicopathological factors[88].

 Yang *et al*[89] investigated the diagnostic value of gastric cancer associated transcript 2 (GACAT2) in GC. In the evaluated cohort, the plasma GACAT2 levels in GC patients were significantly higher compared with healthy individuals, as well as in the preoperative group compared with the postoperative one. In addition, the individual relative changes of GACAT2 expression following surgery were significantly associated with lymphatic metastasis, distal metastasis, and perineural invasion.

 Also, some lncRNAs panels were investigated for GC diagnosis. Zhang *et al*[90] identified a panel of five novel plasma lncRNAs (TINCR, CCAT2, AOC4P, BANCR, and LINC00857) using genome-wide lncRNA screening analysis which could distinguish GC patients from healthy controls and can help monitor tumor dynamics, tumor, depth of invasion, lymphatic metastasis and more advanced tumor stages. Also, Dong *et al*[91] identified a three-lncRNA signature, CUDR, LSINCT-5, and PTENP1, that allows distinguishing healthy controls from early GC patients.

 However, to introduce lncRNAs as plasma biomarkers, further studies and improvements of extraction, quantification, probe enrichment, and evaluation methods should be performed.

**CIRCRNAS, A NEW CLASS OF GC BIOMARKERS**

CircRNAs are a new class of non-coding RNAs that form a closed loop, without 5’ and 3’ ends[92]. CircRNAs were first identified in RNA viruses, but later with the progress of new molecular techniques like high-throughput RNA sequencing and microarray analysis, circRNAs were found in all eukaryotic organisms as stable and conserved sequences that control gene expression through interactions with miRNAs[93]. New emerging data have confirmed that circRNAs are involved in the occurrence of many diseases, and also are strongly associated with tumor growth and metastasis[94]. These findings underline the potential of circRNAs to act as novel biomarkers and therapeutic targets for various human tumors.

 Several recent studies have analyzed the aberrant expression of circRNA in GC compared with adjacent normal tissue and presented various lists with upregulated and downregulated circRNA[95-98] (Table 2). The study performed by Huang *et al*[96] identified circRNA‑0026 (hsa\_circ\_0000026) as having significantly downregulated expression 2.8‑fold change in GC. Sui *et al*[95] found six differentially expressed circRNA in GC tissue and managed to validate through qRT-PCR three of them (hsa\_circRNA\_400071, hsa\_circRNA\_000543, and hsa\_circRNA\_001959) as having a consistent expression with the differentially expressed gene. Through analysis of circRNA and mRNA differential expression profiles in GC tissues, the authors managed to identify the target mRNA and their respective genes for selected circRNAs, like *cd44, cxxc5, myh9,* *malat1* and other genes with important implications in GC tumorigenesis and development.

One important finding related to circRNA in cancer was that they are not easily degraded by RNase and thus, are stably expressed in human cells, in plasma or in gastric juice[104,109]. These findings opened the way for plasma circRNA profiling studies, aiming to identify specific diagnostic and prognostic circRNA for GC patients. Li *et al*[108] performed circRNA microarray for three GC samples and plasma, to assess the differences of circRNA expression profiles. They found that 3 and 14 circRNA were upregulated and downregulated respectively, both in patients’ plasma and tumor tissue. Further, they analyzed through RT-droplet digital PCR (RT-ddPCR) the circRNA levels in plasma for 121 GC patients. Two circRNA: hsa\_circ\_0001017 (30.85-folds change) and hsa\_circ\_0061276 (121.54-folds change) were selected for their non-invasion diagnostic values. Results showed that patients with low level of hsa\_circ\_0001017 or hsa\_circ\_0061276 in plasma had shorter overall survival than those with high levels. Moreover, patients whose plasma levels of the two circRNA recovered to normal after the operation had longer disease-free survival.

 Due to their documented correlation between tissue and plasma level, stability and presence as cell-free RNA in plasma, circRNA may be valuable blood-based biomarkers for GC screening, diagnosis, and prognosis.

**CIRCULATING TUMOR CELLS**

GC diagnosis relies mostly on invasive procedures, which are rather expensive and may have sometimes serious adverse events[110]. In spite of being documented 150 years ago[111], only last years proved that analyzing circulating tumor cells (CTCs) in liquid biopsies, a blood-based diagnostic approach, as a substitute for tissue biopsies have emerged as real-time cancer development monitoring tool and management strategy[112].

 CTCs are a very rare and heterogeneous population of cells circulating in peripheral blood, originating from either primary or metastatic tumors that express the antigenic or genetic characteristics of the specific tumor type[113]. CTCs were first described as expressing epithelial cell markers EpCAM, cytokeratin 8, 18, and 19 (CK8, CK18, CK19), and are CD45 negative[114]. Recently, EMT with potential overexpression of mesenchymal markers and decreased expression of epithelial cell markers or mesenchymal-epithelial transition (MET) that present mesenchymal and epithelial markers, were shown to characterize subpopulations of these cells[115,116]. Mesenchymal phenotypes have larger plasticity thus facilitating migration, invasion, and drug resistance[117]. Several studies revealed the presence of CTCs in circulating tumor microemboli (CTM), indicating poor prognosis and influencing disease progression[118].

 This high heterogeneity of CTCs prompted researchers to develop different methodologies to enrich, isolate and/or enumerate them based on specific phenotypic or molecular characteristics. Basically, there are two general types of methods used in CTCs enrichment/isolation: biological and physical methods. Their combination is more likely to improve the efficiency of CTC detection. CellSearch™ platform (Veridex LLC, Huntingdon Valley, PA, United States) the only procedure approved for the enumeration and isolation of CTCs by the Food and Drug Administration (FDA) for clinical use, detect the adhesion molecule EpCAM, CK8, CK18 and CK19 and exclude CD45 cells but may overlook CTCs with predominantly mesenchymal phenotype. Using cell size - and phenotype-based systems, as centrifugal microfluidic system based on fluid-assisted separation technique (FAST), or Cascaded Inertial Focusing Microfluidic device, coupled with detection of an extended panel of markers might identify a different subpopulation of CTCs with higher efficiency[119,120].

 Exploiting a frequent genetic abnormality reported in GC tumors, the aneuploidy of chromosome 8, Li *et al*[121] created an integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform claimed to be more sensitive than the CellSearch™ to detect and characterize CTCs in advanced GC patients. Multiple studies showed that SET-iFISH method to enumerate CTCs with chromosome 8 aneuploidy is efficient in monitoring GC patient treatment response[113]. Expression of different other markers as vimentin, twist, MUC1, HER2, *etc.* proved to be very useful to evaluate therapeutic response and prognosis in patients with GC. However, irrespective of the detection method employed, there is weak evidence that detection of CTCs has the potential for early biomarker detection in GC but all data are consistent in supporting its utility in assessing the tumor heterogeneity, monitoring treatment responses and real-time cancer management[113].

**CIRCULATING TUMOR DNA**

Circulating tumor DNA (ctDNA) analysis refined the liquid biopsy to the level of identification of tumor molecular traces circulating in the body fluids and may give deeper insight on the cancer heterogeneity, early biomarker detection, therapeutic target detection, real-time evaluation of treatment response and possible resistance and prognosis. Originating from primary tumor cells, CTCs and/or distant metastasis, ctDNA give a broad cross-section of the disease offering information on methylation status, genetic alterations as mutations, amplifications, rearrangements, copy number variation (CNV), the latter being more difficult to analyze due to the short length and possibly unequal distribution of the ctDNA fragments[111].

 Generally, ctDNA represents only a fraction of the cell-free circulating DNA (cfDNA), which is increased considerably in late-stage disease[122]. However, there is evidence that ctDNA can be detected in the plasma of cancer patients even in the early stages of their disease[123,124]. In GC, Fang *et al*[125] found that ctDNA levels were correlated with vascular invasion and the highest ctDNA detectable levels were associated with peritoneal recurrence and a poor prognosis. Balgkouranidou *et al*[126] showed that *rassf1a* and *apc* promoter hypermethylation in cfDNA represents a frequent epigenetic event in patients with early operable GC demonstrating a prognostic capacity for these patients. Another study suggested that cfDNA can identify EBV-associated gastric carcinoma (EBVaGC) subtype and monitor tumor progression as well as treatment response in patients with EBVaGC[127].

 Being a rare event, ctDNA requires highly sensitive and reproducible analytical methods for proper investigation. Multiplex mass spectrometric SNP genotyping technology, real-time quantitative PCR (qRT-PCR), digital droplet PCR (ddPCR) with improved nucleic acid quantification, next-generation sequencing (NGS) were already employed for ctDNA analysis in GC patients[125,128-130] proving the usefulness in personalized treatment decisions. A panel of more than 70 genes and genomic biomarkers for MSI and blood tumor mutational burden (bTMB) by Foundation Medicine, the FoundationACT® assay, was granted breakthrough device designation by the FDA[131] and might become the first FDA-approved liquid biopsy assay to incorporate multiple companion diagnostics (CDx) and multiple biomarkers.

**Conclusion**

GC remains an important cause of cancer death worldwide with a high mortality rate due to the fact that the majority of GC cases are diagnosed at an advanced stage when the prognosis is poor and the treatment options are limited. Unfortunately, the existing circulating biomarkers for GC diagnosis and prognosis display low sensitivity and specificity and the GC diagnosis is based only on the invasive procedures such as upper digestive endoscopy. Therefore, most current GC studies are focused on the identification and validation of non-invasive cancer biomarkers released from the tumor tissues into the body fluids, such as blood and stomach juice. Many of these biomarkers are not specific for the early stages, being detected in advanced stages of GC, and cannot be used for early GC detection. However, some of recently discovered circulating molecules (miRNAs, lncRNAs, circRNA) hold the promise for developing new strategies for early diagnosis of GC, being able to discriminate between the early stage of GC and healthy subjects, with a sensitivity more than 77.5%. In order to improve the sensitivity and enlarge the early stage biomarkers list, further studies should be performed to optimize laboratory techniques such as extraction, quantification, probe enrichment, and evaluation methods. Moreover, these results need to be validated by independent groups or cohorts in prospective studies.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Luo M**, Li L. Clinical utility of miniprobe endoscopic ultrasonography for prediction of invasion depth of early gastric cancer: A meta-analysis of diagnostic test from PRISMA guideline. *Medicine* (Baltimore) 2019; **98**: e14430 [PMID: 30732202 DOI: 10.1097/MD.0000000000014430]

3 **Tsai MM**, Wang CS, Tsai CY, Huang HW, Chi HC, Lin YH, Lu PH, Lin KH. Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer. *Int J Mol Sci* 2016; **17** [PMID: 27322246 DOI: 10.3390/ijms17060945]

4 **Tong W**, Ye F, He L, Cui L, Cui M, Hu Y, Li W, Jiang J, Zhang DY, Suo J. Serum biomarker panels for diagnosis of gastric cancer. *Onco Targets Ther* 2016; **9**: 2455-2463 [PMID: 27217769 DOI: 10.2147/OTT.S86139]

5 **Cisło M**, Filip AA, Arnold Offerhaus GJ, Ciseł B, Rawicz-Pruszyński K, Skierucha M, Polkowski WP. Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. *Oncotarget* 2018; **9**: 19427-19442 [PMID: 29721214 DOI: 10.18632/oncotarget.24827]

6 **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]

7 **Cristescu R**, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, Choi MG, Sohn TS, Lee JH, Bae JM, Kim ST, Park SH, Sohn I, Jung SH, Tan P, Chen R, Hardwick J, Kang WK, Ayers M, Hongyue D, Reinhard C, Loboda A, Kim S, Aggarwal A. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. *Nat Med* 2015; **21**: 449-456 [PMID: 25894828 DOI: 10.1038/nm.3850]

8 **Katona BW**, Rustgi AK. Gastric Cancer Genomics: Advances and Future Directions. *Cell Mol Gastroenterol Hepatol* 2017; **3**: 211-217 [PMID: 28275688 DOI: 10.1016/j.jcmgh.2017.01.003]

9 **Chivu-Economescu M**, Matei L, Necula LG, Dragu DL, Bleotu C, Diaconu CC. New therapeutic options opened by the molecular classification of gastric cancer. *World J Gastroenterol* 2018; **24**: 1942-1961 [PMID: 29760539 DOI: 10.3748/wjg.v24.i18.1942]

10 **Patel TN**, Roy S, Ravi R. Gastric cancer and related epigenetic alterations. *Ecancermedicalscience* 2017; **11**: 714 [PMID: 28144288 DOI: 10.3332/ecancer.2017.714]

11 **Shimada H**, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. *Gastric Cancer* 2014; **17**: 26-33 [PMID: 23572188 DOI: 10.1007/s10120-013-0259-5]

12 **Qian C**, Ju S, Qi J, Zhao J, Shen X, Jing R, Yu J, Li L, Shi Y, Zhang L, Wang Z, Cong H. Alu-based cell-free DNA: a novel biomarker for screening of gastric cancer. *Oncotarget* 2016; **8**: 54037-54045 [PMID: 28903321 DOI: 10.18632/oncotarget.11079]

13 **Kotzev AI**, Draganov PV. Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing? *Gastrointest Tumors* 2018; **5**: 1-13 [PMID: 30574476 DOI: 10.1159/000488240]

14 **Zhang YH**, Li Y, Chen C, Peng CW. Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy. *Hepatogastroenterology* 2009; **56**: 1750-1754 [PMID: 20214231]

15 **Dilege E**, Mihmanli M, Demir U, Ozer K, Bostanci O, Kaya C, Aksakal O, Sakiz D. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. *Hepatogastroenterology* 2010; **57**: 674-677 [PMID: 20698248]

16 **Jin Z**, Jiang W, Wang L. Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). *Oncol Lett* 2015; **9**: 1502-1508 [PMID: 25788990 DOI: 10.3892/ol.2015.2959]

17 **Dolscheid-Pommerich RC**, Manekeller S, Walgenbach-Brünagel G, Kalff JC, Hartmann G, Wagner BS, Holdenrieder S. Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays. *Anticancer Res* 2017; **37**: 353-359 [PMID: 28011514 DOI: 10.21873/anticanres.11329]

18 **Matsuoka T**, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. *World J Gastroenterol* 2018; **24**: 2818-2832 [PMID: 30018477 DOI: 10.3748/wjg.v24.i26.2818]

19 **Feng F**, Tian Y, Xu G, Liu Z, Liu S, Zheng G, Guo M, Lian X, Fan D, Zhang H. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. *BMC Cancer* 2017; **17**: 737 [PMID: 29121872 DOI: 10.1186/s12885-017-3738-y]

20 **Tian SB**, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, Yan C. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. *Asian Pac J Cancer Prev* 2014; **15**: 6295-6300 [PMID: 25124614]

21 **Ning S**, Wei W, Li J, Hou B, Zhong J, Xie Y, Liu H, Mo X, Chen J, Zhang L. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. *J Cancer* 2018; **9**: 494-501 [PMID: 29483954 DOI: 10.7150/jca.21562]

22 **Li J**, Xu L, Run ZC, Feng W, Liu W, Zhang PJ, Li Z. Multiple cytokine profiling in serum for early detection of gastric cancer. *World J Gastroenterol* 2018; **24**: 2269-2278 [PMID: 29881236 DOI: 10.3748/wjg.v24.i21.2269]

23 **Lansdorp-Vogelaar I**, Kuipers EJ. Screening for gastric cancer in Western countries. *Gut* 2016; **65**: 543-544 [PMID: 26611232 DOI: 10.1136/gutjnl-2015-310356]

24 **Kalniņa Z**, Meistere I, Kikuste I, Tolmanis I, Zayakin P, Linē A. Emerging blood-based biomarkers for detection of gastric cancer. *World J Gastroenterol* 2015; **21**: 11636-11653 [PMID: 26556992 DOI: 10.3748/wjg.v21.i41.11636]

25 **Leja M**, You W, Camargo MC, Saito H. Implementation of gastric cancer screening - the global experience. *Best Pract Res Clin Gastroenterol* 2014; **28**: 1093-1106 [PMID: 25439074 DOI: 10.1016/j.bpg.2014.09.005]

26 **Tu H**, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X, Yuan Y. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study. *Am J Gastroenterol* 2017; **112**: 704-715 [PMID: 28323271 DOI: 10.1038/ajg.2017.55]

27 **Xiao P**, Ling H, Lan G, Liu J, Hu H, Yang R. Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer. *Clin Chim Acta* 2015; **450**: 127-134 [PMID: 26265233 DOI: 10.1016/j.cca.2015.08.004]

28 **Lee HS**, Jeon SW, Nomura S, Seto Y, Kwon YH, Nam SY, Ishibashi Y, Ohtsu H, Ohmoto Y, Yang HM. Screening Biomarker as an Alternative to Endoscopy for the Detection of Early Gastric Cancer: The Combination of Serum Trefoil Factor Family 3 and Pepsinogen. *Gastroenterol Res Pract* 2018; **2018**: 1024074 [PMID: 29977284 DOI: 10.1155/2018/1024074]

29 **Fu H**, Cui D. Human Serum Protein Markers for Gastric Cancer Detection. In: Cui D, editor. Gastric Cancer Prewarning and Early Diagnosis System. Dordrecht: Springer Netherlands, 2017: 11-36

30 **Qin R**, Zhao J, Qin W, Zhang Z, Zhao R, Han J, Yang Y, Li L, Wang X, Ren S, Sun Y, Gu J. Discovery of Non-invasive Glycan Biomarkers for Detection and Surveillance of Gastric Cancer. *J Cancer* 2017; **8**: 1908-1916 [PMID: 28819389 DOI: 10.7150/jca.17900]

31 **Kanda M**, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. *World J Gastroenterol* 2015; **21**: 9838-9852 [PMID: 26379391 DOI: 10.3748/wjg.v21.i34.9838]

32 **Deng N**, Liu JW, Sun LP, Xu Q, Duan ZP, Dong NN, Yuan Y. Expression of XPG protein in the development, progression and prognosis of gastric cancer. *PLoS One* 2014; **9**: e108704 [PMID: 25268735 DOI: 10.1371/journal.pone.0108704]

33 **Lee J**, Goh SH, Song N, Hwang JA, Nam S, Choi IJ, Shin A, Kim IH, Ju MH, Jeong JS, Lee YS. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. *Am J Pathol* 2012; **181**: 43-52 [PMID: 22609115 DOI: 10.1016/j.ajpath.2012.03.027]

34 **Zheng H**, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K, Takano Y. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. *Anticancer Res* 2006; **26**: 3579-3583 [PMID: 17094486]

35 **Chen SZ**, Yao HQ, Zhu SZ, Li QY, Guo GH, Yu J. Expression levels of matrix metalloproteinase-9 in human gastric carcinoma. *Oncol Lett* 2015; **9**: 915-919 [PMID: 25621068 DOI: 10.3892/ol.2014.2768]

36 **Xu MD**, Dong L, Qi P, Weng WW, Shen XH, Ni SJ, Huang D, Tan C, Sheng WQ, Zhou XY, Du X. Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer. *Gastric Cancer* 2016; **19**: 107-115 [PMID: 25627474 DOI: 10.1007/s10120-015-0459-2]

37 **Fang Z**, Tian Z, Luo K, Song H, Yi J. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients. *Chin J Cancer Res* 2014; **26**: 602-610 [PMID: 25400427 DOI: 10.3978/j.issn.1000-9604.2014.10.08]

38 **Arigami T**, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N, Matsushita D, Yanagita S, Nakajo A, Okumura H, Hokita S, Natsugoe S. Expression of stanniocalcin 1 as a potential biomarker of gastric cancer. *Oncology* 2012; **83**: 158-164 [PMID: 22889960 DOI: 10.1159/000341390]

39 **Chivu Economescu M**, Necula LG, Dragu D, Badea L, Dima SO, Tudor S, Nastase A, Popescu I, Diaconu CC. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. *Hepatogastroenterology* 2010; **57**: 1453-1464 [PMID: 21443102]

40 **Solé X**, Crous-Bou M, Cordero D, Olivares D, Guinó E, Sanz-Pamplona R, Rodriguez-Moranta F, Sanjuan X, de Oca J, Salazar R, Moreno V. Discovery and validation of new potential biomarkers for early detection of colon cancer. *PLoS One*2014; **9**: e106748 [PMID: 25215506 DOI: 10.1371/journal.pone.0106748]

41 **Chivu-Economescu M**, Dragu DL, Necula LG, Matei L, Enciu AM, Bleotu C, Diaconu CC. Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells. *Gastric Cancer* 2017; **20**: 948-959 [PMID: 28299464 DOI: 10.1007/s10120-017-0712-y]

42 **Sun T**, Du W, Xiong H, Yu Y, Weng Y, Ren L, Zhao H, Wang Y, Chen Y, Xu J, Xiang Y, Qin W, Cao W, Zou W, Chen H, Hong J, Fang JY. TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome. *Clin Cancer Res* 2014; **20**: 4689-4704 [PMID: 24987055 DOI: 10.1158/1078-0432.CCR-14-0315]

43 **Sun TT**, Tang JY, Du W, Zhao HJ, Zhao G, Yang SL, Chen HY, Hong J, Fang JY. Bidirectional regulation between TMEFF2 and STAT3 may contribute to Helicobacter pylori-associated gastric carcinogenesis. *Int J Cancer* 2015; **136**: 1053-1064 [PMID: 24996057 DOI: 10.1002/ijc.29061]

44 **Altieri F**, Di Stadio CS, Federico A, Miselli G, De Palma M, Rippa E, Arcari P. Epigenetic alterations of gastrokine 1 gene expression in gastric cancer. *Oncotarget* 2017; **8**: 16899-16911 [PMID: 28129645 DOI: 10.18632/oncotarget.14817]

45 **Watanabe Y**, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. *Gastroenterology* 2009; **136**: 2149-2158 [PMID: 19375421 DOI: 10.1053/j.gastro.2009.02.085]

46 **Shi J**, Cheng C, Ma J, Liew CC, Geng X. Gene expression signature for detection of gastric cancer in peripheral blood. *Oncol Lett* 2018; **15**: 9802-9810 [PMID: 29928354 DOI: 10.3892/ol.2018.8577]

47 **Pizzi MP**, Bartelli TF, Pelosof AG, Freitas HC, Begnami MD, de Abrantes LLS, Sztokfisz C, Valieris R, Knebel FH, Coelho LGV, da Costa WL Jr, Coimbra FJF, da Silva IT, de Amorim MG, Nunes DN, Dias-Neto E. Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow-up. *Int J Cancer* 2019; : [PMID: 30779121 DOI: 10.1002/ijc.32217]

48 **Qu Y**, Dang S, Hou P. Gene methylation in gastric cancer. *Clin Chim Acta* 2013; **424**: 53-65 [PMID: 23669186 DOI: 10.1016/j.cca.2013.05.002]

49 **Puneet**, Kazmi HR, Kumari S, Tiwari S, Khanna A, Narayan G. Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers. *Pathol Oncol Res* 2018; **24**: 757-770 [PMID: 29552712 DOI: 10.1007/s12253-018-0410-z]

50 **Sepulveda JL**, Gutierrez-Pajares JL, Luna A, Yao Y, Tobias JW, Thomas S, Woo Y, Giorgi F, Komissarova EV, Califano A, Wang TC, Sepulveda AR. High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing. *Mod Pathol* 2016; **29**: 182-193 [PMID: 26769141 DOI: 10.1038/modpathol.2015.144]

51 **Ushijima T**, Sasako M. Focus on gastric cancer. *Cancer Cell* 2004; **5**: 121-125 [PMID: 14998488]

52 **Tahara T**, Arisawa T. DNA methylation as a molecular biomarker in gastric cancer. *Epigenomics* 2015; **7**: 475-486 [PMID: 26077432 DOI: 10.2217/epi.15.4]

53 **Ferrini AM**, Mannoni V, Pontieri E, Pourshaban M. Longer resistance of some DNA traits from BT176 maize to gastric juice from gastrointestinal affected patients. *Int J Immunopathol Pharmacol* 2007; **20**: 111-118 [PMID: 17346434 DOI: 10.1177/039463200702000113]

54 **Yamamoto H**, Watanabe Y, Oikawa R, Morita R, Yoshida Y, Maehata T, Yasuda H, Itoh F. BARHL2 Methylation Using Gastric Wash DNA or Gastric Juice Exosomal DNA is a Useful Marker For Early Detection of Gastric Cancer in an H. pylori-Independent Manner. *Clin Transl Gastroenterol* 2016; **7**: e184 [PMID: 27441821 DOI: 10.1038/ctg.2016.40]

55 **da Silva Oliveira KC**, Thomaz Araújo TM, Albuquerque CI, Barata GA, Gigek CO, Leal MF, Wisnieski F, Rodrigues Mello Junior FA, Khayat AS, de Assumpção PP, Rodriguez Burbano RM, Smith MC, Calcagno DQ. Role of miRNAs and their potential to be useful as diagnostic and prognostic biomarkers in gastric cancer. *World J Gastroenterol* 2016; **22**: 7951-7962 [PMID: 27672290 DOI: 10.3748/wjg.v22.i35.7951]

56 **Link A**, Kupcinskas J. MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. *World J Gastroenterol* 2018; **24**: 3313-3329 [PMID: 30122873 DOI: 10.3748/wjg.v24.i30.3313]

57 **Wu J**, Li G, Wang Z, Yao Y, Chen R, Pu X, Wang J. Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer. *Dis Markers* 2015; **2015**: 435656 [PMID: 26063956 DOI: 10.1155/2015/435656]

58 **Hung PS**, Chen CY, Chen WT, Kuo CY, Fang WL, Huang KH, Chiu PC, Lo SS. miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma. *PLoS One* 2017; **12**: e0177346 [PMID: 28486502 DOI: 10.1371/journal.pone.0177346]

59 **Tsai MM**, Wang CS, Tsai CY, Huang CG, Lee KF, Huang HW, Lin YH, Chi HC, Kuo LM, Lu PH, Lin KH. Circulating microRNA-196a/b are novel biomarkers associated with metastatic gastric cancer. *Eur J Cancer* 2016; **64**: 137-148 [PMID: 27420607 DOI: 10.1016/j.ejca.2016.05.007]

60 **Jiang X**, Wang W, Yang Y, Du L, Yang X, Wang L, Zheng G, Duan W, Wang R, Zhang X, Wang L, Chen X, Wang C. Identification of circulating microRNA signatures as potential noninvasive biomarkers for prediction and prognosis of lymph node metastasis in gastric cancer. *Oncotarget* 2017; **8**: 65132-65142 [PMID: 29029418 DOI: 10.18632/oncotarget.17789]

61 **Zhu C**, Ren C, Han J, Ding Y, Du J, Dai N, Dai J, Ma H, Hu Z, Shen H, Xu Y, Jin G. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. *Br J Cancer* 2014; **110**: 2291-2299 [PMID: 24595006 DOI: 10.1038/bjc.2014.119]

62 **Wang J**, Zhang H, Zhou X, Wang T, Zhang J, Zhu W, Zhu H, Cheng W. Five serum-based miRNAs were identified as potential diagnostic biomarkers in gastric cardia adenocarcinoma. *Cancer Biomark* 2018; **23**: 193-203 [PMID: 30198863 DOI: 10.3233/CBM-181258]

63 **Huang Z**, Zhu D, Wu L, He M, Zhou X, Zhang L, Zhang H, Wang W, Zhu J, Cheng W, Chen Y, Fan Y, Qi L, Yin Y, Zhu W, Shu Y, Liu P. Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer. *Cancer Epidemiol Biomarkers Prev* 2017; **26**: 188-196 [PMID: 27756776 DOI: 10.1158/1055-9965.EPI-16-0607]

64 **Wang N**, Wang L, Yang Y, Gong L, Xiao B, Liu X. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. *Biochem Biophys Res Commun* 2017; **493**: 1322-1328 [PMID: 28986250 DOI: 10.1016/j.bbrc.2017.10.003]

65 **Ranjbar R**, Hesari A, Ghasemi F, Sahebkar A. Expression of microRNAs and IRAK1 pathway genes are altered in gastric cancer patients with Helicobacter pylori infection. *J Cell Biochem* 2018; **119**: 7570-7576 [PMID: 29797599 DOI: 10.1002/jcb.27067]

66 **Virgilio E**, Giarnieri E, Giovagnoli MR, Montagnini M, Proietti A, D'Urso R, Mercantini P, Balducci G, Cavallini M. Gastric Juice MicroRNAs as Potential Biomarkers for Screening Gastric Cancer: A Systematic Review. *Anticancer Res* 2018; **38**: 613-616 [PMID: 29374683 DOI: 10.21873/anticanres.12265]

67 **Valladares-Ayerbes M**, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J, Quindós M, Carral A, Figueroa A, Antón-Aparicio LM, Calvo L. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. *J Transl Med* 2012; **10**: 186 [PMID: 22954417 DOI: 10.1186/1479-5876-10-186]

68 **Liu X**, Kwong A, Sihoe A, Chu KM. Plasma miR-940 may serve as a novel biomarker for gastric cancer. *Tumour Biol* 2016; **37**: 3589-3597 [PMID: 26456959 DOI: 10.1007/s13277-015-4019-5]

69 **Jiang X**, Jiang M, Xu M, Xu J, Li Y. Identification of diagnostic utility and molecular mechanisms of circulating miR-551b-5p in gastric cancer. *Pathol Res Pract* 2019 [PMID: 30732916 DOI: 10.1016/j.prp.2019.01.035]

70 **Tsujiura M**, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. *Br J Cancer* 2010; **102**: 1174-1179 [PMID: 20234369 DOI: 10.1038/sj.bjc.6605608]

71 **Wang J**, Song YX, Wang ZN. Non-coding RNAs in gastric cancer. *Gene* 2015; **560**: 1-8 [PMID: 25659765 DOI: 10.1016/j.gene.2015.02.004]

72 **Shi T**, Gao G, Cao Y. Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics. *Dis Markers* 2016; **2016**: 9085195 [PMID: 27143813 DOI: 10.1155/2016/9085195]

73 **Bolha L**, Ravnik-Glavač M, Glavač D. Long Noncoding RNAs as Biomarkers in Cancer. *Dis Markers* 2017; **2017**: 7243968 [PMID: 28634418 DOI: 10.1155/2017/7243968]

74 **Cao WJ**, Wu HL, He BS, Zhang YS, Zhang ZY. Analysis of long non-coding RNA expression profiles in gastric cancer. *World J Gastroenterol* 2013; **19**: 3658-3664 [PMID: 23801869 DOI: 10.3748/wjg.v19.i23.3658]

75 **Zhou X**, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. *Sci Rep* 2015; **5**: 11516 [PMID: 26096073 DOI: 10.1038/srep11516]

76 **Zhao Y**, Guo Q, Chen J, Hu J, Wang S, Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. *Oncol Rep* 2014; **31**: 358-364 [PMID: 24247585 DOI: 10.3892/or.2013.2850]

77 **Xian HP**, Zhuo ZL, Sun YJ, Liang B, Zhao XT. Circulating long non-coding RNAs HULC and ZNFX1-AS1 are potential biomarkers in patients with gastric cancer. *Oncol Lett* 2018; **16**: 4689-4698 [PMID: 30197680 DOI: 10.3892/ol.2018.9199]

78 **Yuan CL**, Li H, Zhu L, Liu Z, Zhou J, Shu Y. Aberrant expression of long noncoding RNA PVT1 and its diagnostic and prognostic significance in patients with gastric cancer. *Neoplasma* 2016; **63**: 442-449 [PMID: 26925791 DOI: 10.4149/314\_150825N45]

79 **Wang J**, Sun J, Wang J, Song Y, Gao P, Shi J, Chen P, Wang Z. Long noncoding RNAs in gastric cancer: functions and clinical applications. *Onco Targets Ther* 2016; **9**: 681-697 [PMID: 26929639 DOI: 10.2147/OTT.S95412]

80 **Arita T**, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Circulating long non-coding RNAs in plasma of patients with gastric cancer. *Anticancer Res* 2013; **33**: 3185-3193 [PMID: 23898077]

81 **Yörüker EE**, Keskin M, Kulle CB, Holdenrieder S, Gezer U. Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer. *Biomed Rep* 2018; **9**: 181-186 [PMID: 30083318 DOI: 10.3892/br.2018.1116]

82 **Hashad D**, Elbanna A, Ibrahim A, Khedr G. Evaluation of the Role of Circulating Long Non-Coding RNA H19 as a Promising Novel Biomarker in Plasma of Patients with Gastric Cancer. *J Clin Lab Anal* 2016; **30**: 1100-1105 [PMID: 27184562 DOI: 10.1002/jcla.21987]

83 **Li Q**, Shao Y, Zhang X, Zheng T, Miao M, Qin L, Wang B, Ye G, Xiao B, Guo J. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. *Tumour Biol* 2015; **36**: 2007-2012 [PMID: 25391424 DOI: 10.1007/s13277-014-2807-y]

84 **Pang Q**, Ge J, Shao Y, Sun W, Song H, Xia T, Xiao B, Guo J. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. *Tumour Biol* 2014; **35**: 5441-5447 [PMID: 24523021 DOI: 10.1007/s13277-014-1709-3]

85 **Shao Y**, Ye M, Jiang X, Sun W, Ding X, Liu Z, Ye G, Zhang X, Xiao B, Guo J. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. *Cancer* 2014; **120**: 3320-3328 [PMID: 24986041 DOI: 10.1002/cncr.28882]

86 **Elsayed ET**, Salem PE, Darwish AM, Fayed HM. Plasma long non-coding RNA HOTAIR as a potential biomarker for gastric cancer. *Int J Biol Markers* 2018; : 1724600818760244 [PMID: 29683069 DOI: 10.1177/1724600818760244]

87 **Gao J**, Cao R, Mu H. Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer. *Int J Clin Exp Pathol* 2015; **8**: 12936-12942 [PMID: 26722487]

88 **Yang Y**, Shao Y, Zhu M, Li Q, Yang F, Lu X, Xu C, Xiao B, Sun Y, Guo J. Using gastric juice lncRNA-ABHD11-AS1 as a novel type of biomarker in the screening of gastric cancer. *Tumour Biol* 2016; **37**: 1183-1188 [PMID: 26280398 DOI: 10.1007/s13277-015-3903-3]

89 **Tan L**, Yang Y, Shao Y, Zhang H, Guo J. Plasma lncRNA-GACAT2 is a valuable marker for the screening of gastric cancer. *Oncol Lett* 2016; **12**: 4845-4849 [PMID: 28105191 DOI: 10.3892/ol.2016.5297]

90 **Zhang K**, Shi H, Xi H, Wu X, Cui J, Gao Y, Liang W, Hu C, Liu Y, Li J, Wang N, Wei B, Chen L. Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. *Theranostics* 2017; **7**: 213-227 [PMID: 28042329 DOI: 10.7150/thno.16044]

91 **Dong L**, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, Weng WW, Tan C, Sheng WQ, Zhou XY, Du X. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. *Int J Cancer* 2015; **137**: 1128-1135 [PMID: 25694351 DOI: 10.1002/ijc.29484]

92 **Memczak S**, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 2013; **495**: 333-338 [PMID: 23446348 DOI: 10.1038/nature11928]

93 **Chen LL**. The biogenesis and emerging roles of circular RNAs. *Nat Rev Mol Cell Biol* 2016; **17**: 205-211 [PMID: 26908011 DOI: 10.1038/nrm.2015.32]

94 **Li P**, Chen S, Chen H, Mo X, Li T, Shao Y, Xiao B, Guo J. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. *Clin Chim Acta* 2015; **444**: 132-136 [PMID: 25689795 DOI: 10.1016/j.cca.2015.02.018]

95 **Sui W**, Shi Z, Xue W, Ou M, Zhu Y, Chen J, Lin H, Liu F, Dai Y. Circular RNA and gene expression profiles in gastric cancer based on microarray chip technology. *Oncol Rep* 2017; **37**: 1804-1814 [PMID: 28184940 DOI: 10.3892/or.2017.5415]

96 **Huang YS**, Jie N, Zou KJ, Weng Y. Expression profile of circular RNAs in human gastric cancer tissues. *Mol Med Rep* 2017; **16**: 2469-2476 [PMID: 28737829 DOI: 10.3892/mmr.2017.6916]

97 **Vidal AF**, Ribeiro-Dos-Santos AM, Vinasco-Sandoval T, Magalhães L, Pinto P, Anaissi AKM, Demachki S, de Assumpção PP, Dos Santos SEB, Ribeiro-Dos-Santos Â. The comprehensive expression analysis of circular RNAs in gastric cancer and its association with field cancerization. *Sci Rep* 2017; **7**: 14551 [PMID: 29109417 DOI: 10.1038/s41598-017-15061-w]

98 **Shen Y**, Zhang J, Fu Z, Zhang B, Chen M, Ling X, Zou X. Gene microarray analysis of the circular RNAs expression profile in human gastric cancer. *Oncol Lett*2018; **15**: 9965-9972 [PMID: 29928369 DOI: 10.3892/ol.2018.8590]

99 **Li P**, Chen H, Chen S, Mo X, Li T, Xiao B, Yu R, Guo J. Circular RNA 0000096 affects cell growth and migration in gastric cancer. *Br J Cancer* 2017; **116**: 626-633 [PMID: 28081541 DOI: 10.1038/bjc.2016.451]

100 **Fang Y**, Ma M, Wang J, Liu X, Wang Y. Circular RNAs play an important role in late-stage gastric cancer: Circular RNA expression profiles and bioinformatics analyses. *Tumour Biol* 2017; **39**: 1010428317705850 [PMID: 28639908 DOI: 10.1177/1010428317705850]

101 **Huang M**, He YR, Liang LC, Huang Q, Zhu ZQ. Circular RNA hsa\_circ\_0000745 may serve as a diagnostic marker for gastric cancer. *World J Gastroenterol* 2017; **23**: 6330-6338 [PMID: 28974900 DOI: 10.3748/wjg.v23.i34.6330]

102 **Zhao Q**, Chen S, Li T, Xiao B, Zhang X. Clinical values of circular RNA 0000181 in the screening of gastric cancer. *J Clin Lab Anal* 2018; **32**: e22333 [PMID: 28940688 DOI: 10.1002/jcla.22333]

103 **Lai Z**, Yang Y, Yan Y, Li T, Li Y, Wang Z, Shen Z, Ye Y, Jiang K, Wang S. Analysis of co-expression networks for circular RNAs and mRNAs reveals that circular RNAs hsa\_circ\_0047905, hsa\_circ\_0138960 and has-circRNA7690-15 are candidate oncogenes in gastric cancer. *Cell Cycle* 2017; **16**: 2301-2311 [PMID: 28980874 DOI: 10.1080/15384101.2017.1380135]

104 **Shao Y**, Li J, Lu R, Li T, Yang Y, Xiao B, Guo J. Global circular RNA expression profile of human gastric cancer and its clinical significance. *Cancer Med* 2017; **6**: 1173-1180 [PMID: 28544609 DOI: 10.1002/cam4.1055]

105 **Shao Y**, Chen L, Lu R, Zhang X, Xiao B, Ye G, Guo J. Decreased expression of hsa\_circ\_0001895 in human gastric cancer and its clinical significances. *Tumour Biol* 2017; **39**: 1010428317699125 [PMID: 28443463 DOI: 10.1177/1010428317699125]

106 **Sun H**, Tang W, Rong D, Jin H, Fu K, Zhang W, Liu Z, Cao H, Cao X. Hsa\_circ\_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. *Cancer Biomark* 2018; **21**: 299-306 [PMID: 29103021 DOI: 10.3233/CBM-170379]

107 **Chen S**, Li T, Zhao Q, Xiao B, Guo J. Using circular RNA hsa\_circ\_0000190 as a new biomarker in the diagnosis of gastric cancer. *Clin Chim Acta* 2017; **466**: 167-171 [PMID: 28130019 DOI: 10.1016/j.cca.2017.01.025]

108 **Li T**, Shao Y, Fu L, Xie Y, Zhu L, Sun W, Yu R, Xiao B, Guo J. Plasma circular RNA profiling of patients with gastric cancer and their droplet digital RT-PCR detection. *J Mol Med* (Berl) 2018; **96**: 85-96 [PMID: 29098316 DOI: 10.1007/s00109-017-1600-y]

109 **Jeck WR**, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA* 2013; **19**: 141-157 [PMID: 23249747 DOI: 10.1261/rna.035667.112]

110 **Levy I**, Gralnek IM. Complications of diagnostic colonoscopy, upper endoscopy, and enteroscopy. *Best Pract Res Clin Gastroenterol* 2016; **30**: 705-718 [PMID: 27931631 DOI: 10.1016/j.bpg.2016.09.005]

111 **Neumann MHD**, Bender S, Krahn T, Schlange T. ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress. *Comput Struct Biotechnol J*2018; **16**: 190-195 [PMID: 29977481 DOI: 10.1016/j.csbj.2018.05.002]

112 **Pantel K**, Alix-Panabières C. Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 73-74 [PMID: 28096542 DOI: 10.1038/nrgastro.2016.198]

113 **Uchôa Guimarães CT**, Ferreira Martins NN, Cristina da Silva Oliveira K, Almeida CM, Pinheiro TM, Gigek CO, Roberto de Araújo Cavallero S, Assumpção PP, Cardoso Smith MA, Burbano RR, Calcagno DQ. Liquid biopsy provides new insights into gastric cancer. *Oncotarget* 2018; **9**: 15144-15156 [PMID: 29599934 DOI: 10.18632/oncotarget.24540]

114 **Allard WJ**, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004; **10**: 6897-6904 [PMID: 15501967 DOI: 10.1158/1078-0432.CCR-04-0378]

115 **Guan X**, Ma F, Liu S, Wu S, Xiao R, Yuan L, Sun X, Yi Z, Yang H, Xu B. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. *Oncotarget* 2016; **7**: 65993-66002 [PMID: 27602758 DOI: 10.18632/oncotarget.11787]

116 **Friedlander TW**, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. *Pharmacol Ther* 2014; **142**: 271-280 [PMID: 24362084 DOI: 10.1016/j.pharmthera.2013.12.011]

117 **Liu H**, Zhang X, Li J, Sun B, Qian H, Yin Z. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. *J Cancer Res Clin Oncol* 2015; **141**: 189-201 [PMID: 24965746 DOI: 10.1007/s00432-014-1752-x]

118 **Chinen LTD**, Abdallah EA, Braun AC, Flores BCTCP, Corassa M, Sanches SM, Fanelli MF. Circulating Tumor Cells as Cancer Biomarkers in the Clinic. *Adv Exp Med Biol* 2017; **994**: 1-41 [PMID: 28560666 DOI: 10.1007/978-3-319-55947-6\_1]

119 **Kang HM**, Kim GH, Jeon HK, Kim DH, Jeon TY, Park DY, Jeong H, Chun WJ, Kim MH, Park J, Lim M, Kim TH, Cho YK. Circulating tumor cells detected by lab-on-a-disc: Role in early diagnosis of gastric cancer. *PLoS One* 2017; **12**: e0180251 [PMID: 28662130 DOI: 10.1371/journal.pone.0180251]

120 **Abdulla A**, Liu W, Gholamipour-Shirazi A, Sun J, Ding X. High-Throughput Isolation of Circulating Tumor Cells Using Cascaded Inertial Focusing Microfluidic Channel. *Anal Chem* 2018; **90**: 4397-4405 [PMID: 29537252 DOI: 10.1021/acs.analchem.7b04210]

121 **Li Y**, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP, Shen L. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. *Oncotarget* 2014; **5**: 6594-6602 [PMID: 25026283 DOI: 10.18632/oncotarget.2175]

122 **Bettegowda C**, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014; **6**: 224ra24 [PMID: 24553385 DOI: 10.1126/scitranslmed.3007094]

123 **Alix-Panabières C**, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov* 2016; **6**: 479-491 [PMID: 26969689 DOI: 10.1158/2159-8290.CD-15-1483]

124 **Sumbal S**, Javed A, Afroze B, Zulfiqar HF, Javed F, Noreen S, Ijaz B. Circulating tumor DNA in blood: Future genomic biomarkers for cancer detection. *Exp Hematol*2018; **65**: 17-28 [PMID: 29940219 DOI: 10.1016/j.exphem.2018.06.003]

125 **Fang WL**, Lan YT, Huang KH, Liu CA, Hung YP, Lin CH, Jhang FY, Chang SC, Chen MH, Chao Y, Lin WC, Lo SS, Fen-Yau Li A, Wu CW, Chiou SH, Shyr YM. Clinical significance of circulating plasma DNA in gastric cancer. *Int J Cancer* 2016; **138**: 2974-2983 [PMID: 26815009 DOI: 10.1002/ijc.30018]

126 **Balgkouranidou I**, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. *Mutat Res* 2015; **778**: 46-51 [PMID: 26073472 DOI: 10.1016/j.mrfmmm.2015.05.002]

127 **Shoda K**, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Kosuga T, Komatsu S, Shiozaki A, Okamoto K, Imoto I, Otsuji E. Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer. *Oncotarget* 2017; **8**: 28796-28804 [PMID: 28430637 DOI: 10.18632/oncotarget.15675]

128 **Shoda K**, Masuda K, Ichikawa D, Arita T, Miyakami Y, Watanabe M, Konishi H, Imoto I, Otsuji E. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. *Gastric Cancer* 2015; **18**: 698-710 [PMID: 25322965 DOI: 10.1007/s10120-014-0432-5]

129 **Shoda K**, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Komatsu S, Shiozaki A, Kakihara N, Okamoto K, Taniguchi H, Imoto I, Otsuji E. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. *Gastric Cancer* 2017; **20**: 126-135 [PMID: 26874951 DOI: 10.1007/s10120-016-0599-z]

130 **Kato S**, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. *Clin Cancer Res* 2018; **24**: 6248-6256 [PMID: 30348637 DOI: 10.1158/1078-0432.CCR-18-1128]

131 Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration 2018. [cited Feb 28 2019]. Available from: http://investors.foundationmedicine.com/news-releases/news-release-details/foundation-medicines-new-liquid-biopsy-assay-granted

 **P-Reviewer:** Aoyagi K, Chiu CC, Kim BW, Tanabe S

**S-Editor:** Ma RY **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Romania

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1** **Possible non-invasive diagnostic biomarkers for early-stage gastric cancer.** Genetic and epigenetic alterations, microRNAs, long non-coding RNAs and circular RNA, circulating tumor cells and tumor DNA represent promising candidates for the development of new non-invasive methods in early-diagnosis of gastric cancer. GC: Gastric cancer; miRNAs: MicroRNAs; lncRNAs: Long non-coding RNAs; circRNA: circular RNA; CTCs: Circulating tumor cells; cfDNAs: Cell-free circulating DNA.



**Figure 2 Methylation changes in gastric cancer.** Epigenetic alteration by methylation occurs in specific genes involved in various processes such as cell cycle regulation, DNA repair, cell growth/differentiation, transcriptional regulation, cell adhesion/invasion/migration, apoptosis, angiogenesis, as well as in multidrug resistance genes, and in genes associated with Epstein-Barr virus-type tumors or *Helicobacter pylori* positive tumors. These gene alterations are correlated with tumor size, localization, differentiation, invasion, lymph node metastasis, distant metastasis, TNM stage, and prognosis. GC: Gastric cancer.

**Table 1 Dysregulated circulating microRNAs reported in gastric cancer patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **microRNA** | **Biological function** | **Type of biomarker** | **Origin of specimen** | **Sensitivity/specificity** | **Study** |
| miR-21 | Upregulated; discriminates between stage I and stage IV of GC | Diagnostic, prognostic | Serum, PBMC | 88.4%/79.6% (serum)81.3%/73.4%(PBMC) | Wu *et al*[57] |
| miR-196a/b | Upregulated; correlated with metastatic potential of the tumor, advanced stages, and poorer survival | Diagnostic, prognostic | Plasma | 69.5%/97.6% | Tsai *et al*[59] |
| miR-200c | Upregulated; predictor of progression and survival. | Diagnostic, prognostic | Blood | 65.4%/100% | Valladares-ayerbes *et al*[67] |
| miR-940 | Downregulated | Diagnostic | Plasma | 81.25 %/98.57 % | Liu *et al*[68] |
| miR-551b-5p | Upregulated | Diagnostic | Serum | 77.5%/80.0% | Jiang *et al*[69] |
| miR-19b, miR-106a | Upregulated; correlated with lymphatic metastasis and advanced stages | Diagnostic, prognostic | Circulating exosomes | 95%/90% | Wang *et al*[64] |
| miR-501-3p, miR-143-3p, miR-451a, miR-146a | Differentially expressed; prediction and prognosis of lymph node metastasis | Prognostic | Serum | 87.78%/63.33% | Jiang *et al*[60] |
| miR-16, miR-25, miR-92a, miR-451, miR-486-5p | Differentially expressed; discriminate between early-stage of GC and cancer-free subjects | Diagnostic | Plasma | 72.9%/89.2% | Zhu *et al*[61] |
| miR-200a-3p, miR-296-5p, miR-132-3p, miR-485-3p, miR-22-5p | Upregulated | Diagnostic | Serum | N/S | Wang *et al*[62] |
| miR10b-5p, miR132-3p, miR185-5p, miR195-5p, miR-20a3p, miR296-5p | Upregulated | Diagnostic | Serum | N/S | Huang *et al*[63] |
| miR-17-5p, miR-21, miR-106a, miR-106b, let-7a | Differentially expressed | Diagnostic | Plasma | 85.5%/80.0% | Tsujiura *et al*[70] |
| miR-146, miR-375, let-7, miR-19, miR-21 | Differentially expressed in GC patients with *H. Pylori* infection | Diagnostic | Plasma | N/S | Ranjbar *et al*[65] |

miR-: MicroRNA; GC: Gastric cancer; PBMC: Peripheral blood mononuclear cell; *H. pylori*: *Helicobacter pylori*;N/S: Not specified.

**Table 2** **Various aberrantly expressed circular RNAs with the potential to serve as diagnostic and prognostic biomarkers for gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **circRNA name** | **Biological function** | **Type of biomarker** | **Origin of specimen** | **Sensitivity/specificity** | **Study** |
| hsa\_circ\_002059 | Downregulated in GC; correlated with TNM stage and metastasis | Diagnostic | Tissues; plasma | 81%/62% | Li *et al*[94] |
| hsa\_circ\_0000096 | Downregulated in GC; affects GC cell growth and migration | Diagnostic | Tissues | N/S | Li *et al*[99] |
| hsa\_circ\_0058246 | Upregulated in GC; associated with poor clinical outcomes | Prognostic | Tissues | N/S | Fang *et al*[100] |
| hsa\_circ\_0000745 | Downregulated in GC; correlated with tumor differentiation and tumor nodal metastasis | Prognostic | Tissues | 85.5%/45% | Huang *et al*[101] |
| hsa\_circ\_00000181 | Downregulated in GC; associated with TNM stage and metastasis | Prognostic | Plasma | 99%/85.2% | Zhao *et al*[102] |
| hsa\_circ\_0047905,has-circRNA7690-15, hsa\_circ\_0138960 | Substantially upregulated in GC; act as tumor promoters in the pathogenesis of GC | Diagnostic | Tissues | N/S | Lai *et al*[103] |
| hsa\_circ\_0014717 | Downregulated in GC; stably expressed in gastric juice; associated with TNM stage and metastasis | Prognostic | Tissues | 59.38%/81.25% | Shao *et al*[104] |
| hsa\_circ\_0001895 | Downregulated in both GC tissue and gastric precancerous lesions | Diagnostic | Tissues | 67.8%/85.7% | Shao *et al*[105] |
| has\_circ\_0000520 | Downregulated in GC; associated with TNM stage and in GC plasma linked with CEA expression | Diagnostic | Tissues; plasma | 53.57%/85.71% (tissue)82.35%/84.44% (plasma) | Sun *et al*[106] |
| hsa\_circ\_0000190 | Downregulated in GC; associated with TNM stage and metastasis | Diagnostic | Tissues; plasma | 71.2%/75% | Chen *et al*[107] |
| hsa\_circ\_0001017 hsa\_circ\_0061276 | Downregulated in GC; associated with shorter overall survival | Prognostic | Tissues; plasma | 95.5%/95.7% | Li *et al*[108] |

GC: Gastric cancer; CEA: Carcinoembryonic antigen; circRNA: Circular RNA; N/S: Not specified.